StageDebt | Alive
Last Raised$15M | 8 mos ago
Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+60 points in the past 30 days
About Scopio Labs
Scopio Labs develops digital microscopes based on computational imaging, in addition to dedicated image analysis tools for various medical fields. It harnesses computational photography and artificial intelligence (AI) to image and analyze the morphology of cells. It develops a diagnostics platform based on advanced digital microscopy. The company was founded in 2015 and is based in Tel Aviv, Israel.
Compete with Scopio Labs?
Ensure that your company and products are accurately represented on our platform.
Scopio Labs's Products & Differentiators
Scopio Labs Full Field Peripheral Blood Smear Application
Scopio are addressing a worldwide problem of the delayed diagnosis and treatment hampered by the lack of innovation in first-line laboratory testing and the manual process still being used in the review of PBS. The FF-PBS Application allows for scanning peripheral blood smears, creating high resolution images combined with powerful AI to automatically detect, classify and quantify the cells, enabling the hematopathologist to view up to 200 cells on a peripheral blood smear with significantly greater consistency, efficiency and speed, and true remote review capabilities. Thus, Scopio has created a complete digital transformation of cell morphology analysis which completely supplants or replaces the manual microscope. With a digital end-to-end solution and relevant workflow tools,Scopio allows for faster, more accurate diagnoses.
Expert Collections containing Scopio Labs
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Scopio Labs is included in 5 Expert Collections, including Artificial Intelligence.
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Scopio Labs Patents
Scopio Labs has filed 17 patents.
The 3 most popular patent topics include:
- Image processing
Metamaterials, Fluid dynamics, Microscopy, Optical devices, Geometrical optics
Metamaterials, Fluid dynamics, Microscopy, Optical devices, Geometrical optics
Latest Scopio Labs News
May 29, 2023
News provided by Share this article Share this article The alliance between Siemens Healthineers and Scopio Labs will revolutionize the way laboratorians view patient samples—from under a microscope to digitized slides. Scopio Labs has granted to Siemens Healthineers global rights to distribute the Scopio X100 and Scopio X100HT, digital solutions that offer full-field imaging and an AI-powered Decision Support System with remote viewing capabilities. Scopio Labs' groundbreaking technology complements Siemens Healthineers' existing hematology portfolio to provide more expansive end-to-end workflow solutions. TEL AVIV, Israel and TARRYTOWN, N.Y., May 8, 2023 /PRNewswire/ -- Siemens Healthineers announced today its entrance into an agreement to distribute Scopio Labs' full-field digital cell morphology technology, which will enable clinical laboratorians to examine patient blood cell samples digitally instead of under a microscope. The Scopio X100 and Scopio X100HT imaging platforms1 will complement the Siemens Healthineers systems— including the Atellica HEMA 570 and Atellica HEMA 580 Analyzers2—to offer labs high-resolution, full-field viewing for peripheral blood specimens and artificial intelligence-based morphological analysis with remote capabilities through the secure hospital network. "By offering laboratorians access to novel digital hematology technologies in one of the lab's busiest testing disciplines, we will be providing critical tools to optimize operational workflow and laboratory efficiency, accelerate diagnosis, and improve patient care while addressing reduced resource capacity," said Sharon Bracken, Head of Diagnostics, Siemens Healthineers. "The alliance between Siemens Healthineers and Scopio Labs is a step forward in delivering automated and digitized solutions that would redefine hematology workflow." The Scopio digital cell morphology platforms are intended for use in the central laboratory adjacent to hematology analyzers to examine patient blood cell samples digitally and remotely, instead of on a slide under a microscope. A patient sample is run on a hematology analyzer. When abnormalities in a patient blood sample are detected or further analysis is required, a blood smear is prepared, and the slide is transferred to the Scopio imaging platform for digitalization. Traditional manual microscopy requires specialized laboratory staff to examine slides and is time-consuming due to the volume of testing and the scope of analysis required for abnormal patient samples. Attempts to digitize cell samples have often faced a tradeoff—increasing resolution versus field of view—both of which contain essential clinical information pertinent for patient care. Scopio Labs' full-field imaging technology provides both the clinical big picture and the smallest details of a cell at the same time. Integrated AI decision support gives laboratory professionals a highly efficient way to standardize WBC differentials, RBC blood morphology, and platelet estimations. Remote review capabilities mean laboratory professional expertise will no longer be limited by physical location, and health care networks can provide fast analyses for their patients while better managing professional resources at their institutions. Scopio's Full-Field Peripheral Blood Smear Application has been shown to reduce turnaround time for peripheral blood smear review by 60 percent—a significant optimization of lab workflows and operational efficiencies.3 "We are proud to collaborate with Siemens Healthineers, a global pioneer in healthcare innovation, imaging, and clinical data management," said Itai Hayut, CEO and cofounder of Scopio Labs. "With Siemens Healthineers' strong focus on data-driven clinical decision-making and our shared mission to innovate and shape the future of hematology, we are excited to include our Full-Field Cell Morphology imaging and analysis platforms as a part of their extensive laboratory diagnostics portfolio. This partnership will help accelerate digital workflow transformation in hematology laboratories worldwide to enhance clinical decisions for optimal patient care." The X100HT can meet the turnaround time requirements of large hospitals and labs, offering throughput of up to 40 samples per hour. The X100 offers a throughput of up to 15 samples per hour. The Full-Field Peripheral Blood Smear Application on the X100HT and the X100 is available for sale in the US and EU. To learn more, visit the Siemens Healthineers booth at ISLH (May 11-13, New Orleans, USA) or EUROMEDLAB (May 22-24, Rome, Italy) or visit Siemens Healthineers and Scopio Labs . About Scopio Labs Scopio Labs' suite of digital imaging and analysis platforms supports laboratory experts with timely detection of blood-related medical conditions, expediting patients' access to life-saving treatments. Scopio solves the age-old tradeoff between resolution and field of view, enabling unprecedented scale and depth in cell morphology. High-resolution imaging and embedded AI combine for more efficient workflow, contributing to better diagnostics across the continuum of care. Scopio Labs' Full-Field Peripheral Blood Smear™ Application is FDA-cleared and CE-marked for use with the Scopio X100 and Scopio X100HT high-resolution scanners. The Full-Field Bone Marrow Aspirate™ Application is CE-marked for use with both devices. To learn more, visit scopiolabs.com . About Siemens Healthineers Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion. Further information is available at www.siemens-healthineers.com . 1 The products/features mentioned here are not commercially available in all countries. 2 The Atellica Hematology Portfolio is not available for sale in the U.S. The products/features mentioned here are not commercially available in all countries. Their future availability cannot be guaranteed. 3 Katz B-Z, et al. Evaluation of Scopio Labs X100 Full Field PBS: The first high-resolution full field viewing of peripheral blood specimens combined with artificial intelligence-based morphological analysis. Int J Lab Hematol. 2021;00:1–9. https://doi.org/10.1111/ijlh.13681 SOURCE Scopio Labs
Scopio Labs Frequently Asked Questions (FAQ)
When was Scopio Labs founded?
Scopio Labs was founded in 2015.
Where is Scopio Labs's headquarters?
Scopio Labs's headquarters is located at 10 Hasharon Street, Tel Aviv.
What is Scopio Labs's latest funding round?
Scopio Labs's latest funding round is Debt.
How much did Scopio Labs raise?
Scopio Labs raised a total of $88M.
Who are the investors of Scopio Labs?
Investors of Scopio Labs include Kreos Capital, Aurum Ventures, Mizrahi Tefahot Bank, OurCrowd First, Ilex Medical and 6 more.
Who are Scopio Labs's competitors?
Competitors of Scopio Labs include SigTuple and 1 more.
What products does Scopio Labs offer?
Scopio Labs's products include Scopio Labs Full Field Peripheral Blood Smear Application and 3 more.
Compare Scopio Labs to Competitors
SigTuple develops medical solutions based on robotics and artificial intelligence (AI) for high-volume screening tests requiring manual analysis of visual medical data. It also develops a cloud-based system to run the operations of a diagnostic lab. The company automates the job of a pathologist by studying microscopic images of blood samples, interpreting them, and issuing reports. It was founded in 2015 and is based in Bangalore, India.
VitruvianMD offers a digital platform that specializes in medical diagnosis services through artificial intelligence (AI) technology.
Oxford Immune Algorithmics develops a medical device designed to assist in blood analytics and remote health monitoring. The company's device performs remote blood testing and assesses the risk from home for a particular condition, enabling doctors to monitor their patient's health in an enhanced manner. It was founded in 2018 and is based in Reading, England.
NTP is an Italian company that operates in the fields of biotechnology and nanotechnology that has designed an optical-laser detector that is able to capture high resolution images, and also to detect nanoparticles of subdiffrattive size.
Sight Diagnostics provides affordable and accurate diagnostics in a compact platform designed for use in qualified labs in low volume settings. Its proprietary machine-vision based technology provides the capability to perform multiple tests on a single, easy-to-operate platform.
Sevamob provides an artificial intelligence (AI) assisted disease management platform. The platform uses deep learning (DL), machine learning (ML), and computer vision to predict medical conditions from symptoms, consultation for diet, point-of-care screening for blood, vision and sputum, and more. It was founded in 2014 and is based in Lucknow, India.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.